Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Insider

AZN

Astrazeneca plc

Feb 10 • 12:09PM ET

193.31

+5.30 2.82 %

Healthcare • Drug Manufacturers - General • United Kingdom • NYSE

Today, 12:10 PMAstraZeneca beats Q4 2025 estimates with non-GAAP EPS $2.12 and revenue $15.5B, raises dividend 3%, and guides 2026 to mid- to high-single-digit revenue and low double-digit EPS growth; says in-licensed oral GLP-1 agonist elecoglipron met Phase II VISTA and SOLSTICE primary endpoints and will advance to several Phase III trials in obesity and diabetes.

Held by: PVAL AVDE DIHP DFIC PPH FVD DFAX PLDR APIE RODM

Scroll to Statements

Index	-	P/E	32.10	EPS (ttm)	6.02	Insider Own	4.81%	Shs Outstand	1.55B	Perf Week	4.88%
Market Cap	299.72B	Forward P/E	16.70	EPS next Y	11.58	Insider Trans	0.00%	Shs Float	1.48B	Perf Month	1.22%
Enterprise Value	324.25B	PEG	1.36	EPS next Q	2.51	Inst Own	53.84%	Short Float	-	Perf Quarter	18.11%
Income	9.40B	P/S	5.16	EPS this Y	12.23%	Inst Trans	-2.58%	Short Ratio	-	Perf Half Y	31.24%
Sales	58.13B	P/B	6.53	EPS next Y	12.62%	ROA	8.57%	Short Interest	-	Perf YTD	10.15%
Book/sh	29.60	P/C	36.63	EPS next 5Y	12.26%	ROE	21.70%	52W High	195.00 -0.87%	Perf Year	44.35%
Cash/sh	5.28	P/FCF	22.88	EPS past 3/5Y	285.86% 34.63%	ROIC	13.06%	52W Low	122.26 58.11%	Perf 3Y	52.89%
Dividend Est.	3.42 (1.77%)	EV/EBITDA	16.83	Sales past 3/5Y	12.64% 17.27%	Gross Margin	73.23%	Volatility	2.87% 2.92%	Perf 5Y	74.70%
Dividend TTM	3.16 (1.63%)	EV/Sales	5.58	EPS Y/Y TTM	44.64%	Oper. Margin	21.86%	ATR (14)	6.70	Perf 10Y	315.45%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.69	Sales Y/Y TTM	13.52%	Profit Margin	16.17%	RSI (14)	57.45	Recom	1.63
Dividend Gr. 3/5Y	2.80% 2.47%	Current Ratio	0.88	EPS Q/Q	77.36%	SMA20	3.90%	Beta	0.39	Target Price	213.51
Payout	69.15%	Debt/Eq	0.71	Sales Q/Q	11.99%	SMA50	4.79%	Rel Volume	10.01	Prev Close	188.01
Employees	94300	LT Debt/Eq	0.57	Earnings	Feb 10 BMO	SMA200	21.39%	Avg Volume	334.50K	Price	193.31
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.32% 0.38%	Trades		Volume	1,463,625	Change	2.82%

Today 12:02PM	AstraZeneca bets on continued oncology demand for 2026 growth (Pharmaceutical Technology)
11:56AM	AstraZeneca Reiterates $80 Billion 2030 View Ahead Of 'Catalyst-Rich 2026' (Investor's Business Daily)
11:27AM	AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials (Clinical Trials Arena)
10:59AM	Jim Cramer on AstraZeneca: "We Want Every Drug Stock" (Insider Monkey)
09:42AM	AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook (Zacks)
09:41AM	Loading…
09:41AM	BP, Ferrari, TSMC: Global Earnings in Focus (The Wall Street Journal)
09:30AM	Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings (Zacks)
09:09AM	AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat (Investor's Business Daily)
08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
08:18AM	Ferrari, BP, TSMC: Global Earnings in Focus (The Wall Street Journal)
07:41AM	BP, Ferrari, TSMC: Earnings and Sales Globally in Focus (The Wall Street Journal)
07:00AM	AstraZeneca results: FY and Q4 2025 (Business Wire)
06:45AM	AstraZenecas growth engine stays on track despite cost pressures (Proactive)
06:33AM	AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 (The Wall Street Journal)
06:22AM	AstraZeneca profit jumps as cancer drug sales grow (AFP)
06:18AM	Loading…
06:18AM	Stocks mostly rise tracking tech, earnings (AFP)
05:27AM	BP, Kering, Barclays: Earnings Around the World in Focus (The Wall Street Journal)
05:27AM	BP, Barclays, TSMC: Global Earnings and Sales in Focus (The Wall Street Journal)
03:06AM	AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations; stock up (Investing.com)
02:35AM	Astrazeneca: Q4 Earnings Snapshot (Associated Press Finance)
02:34AM	AstraZeneca Forecasts Continued Growth on Pipeline Strength (The Wall Street Journal)
02:24AM	AstraZeneca profit climbs on cancer and heart drug demand (MarketWatch)
02:08AM	AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth (Proactive)
Feb-09-26 07:00PM	Robinhood earnings, Fed comments, retail sales: What to Watch (Yahoo Finance Video)
11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
10:44AM	Dow Jones retreat from highs as Amazon and Apple fall (Proactive)
09:39AM	Week ahead: Markets to test rebound with earnings, jobs data due (Proactive)
09:24AM	J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss (Zacks)
09:11AM	Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? (Zacks)
07:16AM	AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
02:30AM	Loading…
02:30AM	Jobs Report, CPI Data: What to Watch This Week (The Wall Street Journal)
Feb-06-26 07:00PM	Super Bowl LX, Coinbase earnings, jobs data & CPI: What to Watch (Yahoo Finance Video)
06:45PM	Jobs Report, CPI Data: What to Watch Next Week (The Wall Street Journal)
05:13PM	TrumpRx Is Here. Most People Wont Benefit. (Barrons.com)
11:58AM	TrumpRx launches to slash drug prices for cash-paying US patients (Pharmaceutical Technology)
08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily)
07:08AM	White Houses online service for drug sales debuts with limited impact on prices (BioPharma Dive)
06:30AM	Broker initiates coverage of Capita with a 'buy' call (Proactive)
12:13AM	Trump Says People Will 'Save A Lot Of Money And Be Healthy' With Launch Of TrumpRx Website - But Will It Actually Fill Prescriptions? (Benzinga)
Feb-05-26 09:17PM	Trump launches TrumpRX website offering discounted prescription drugs (Investing.com)
09:15AM	Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-04-26 12:30PM	Shell chief exec to become one of FTSEs best paid bosses (The Telegraph)
12:29PM	Health Care Roundup: Market Talk (The Wall Street Journal)
10:19AM	AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus (Zacks)
10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 06:15PM	Why Astrazeneca (AZN) Dipped More Than Broader Market Today (Zacks)
02:30PM	AstraZeneca Stock Soared 103% Monday, Holding At High Level. Gets Rating Upgrade. (Investor's Business Daily)
11:48AM	FDA Rejects AstraZeneca's Saphnelo Injection, Shares Drop 1.9% (GuruFocus.com)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
11:34AM	Jim Cramer Says "I Like AstraZeneca Very Much" (Insider Monkey)
11:02AM	Walmart hits $1 trillion market cap, joins tech giants (Investing.com)
07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy (Business Wire)
06:55AM	AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot (Benzinga)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:34AM	AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals (Insider Monkey)
02:42AM	AstraZenecas Initial Application for Lupus Injection Turned Down by FDA (The Wall Street Journal)
Feb-02-26 02:15PM	Should You Buy the Dip in IonQ Stock? (Barchart)
02:04PM	US and India reach trade deal, Astrazeneca shares move to NYSE (Yahoo Finance Video)
12:29PM	AstraZeneca Moves to NYSE as $50 Billion US Investment Plan Takes Focus (GuruFocus.com)
11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
07:00AM	AstraZeneca begins trading on the New York Stock Exchange (Business Wire)
02:46AM	AstraZeneca Shares to Start Trading in US After Listing Upgrade (Bloomberg)
Jan-30-26 12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:11AM	Block quotes in PNR test (Test Provider for Finance)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

AZN

Astrazeneca plc

Upgrade your FINVIZ experience